Key result
Visfatin induced cardiomyocyte hypertrophy through the activation of the ERK1/2 signaling pathway, an effect significantly attenuated by pre-treatment with MAPK Kinase Inhibitor PD98059.
Why the study?
Visfatin induces inflammatory factors and myocardial hypertrophy, but the exact molecular mechanisms underlying visfatin-induced cardiomyocyte hypertrophy remain unclear.
Does visfatin induce cardiomyocyte hypertrophy via the ERK1/2 signaling pathway in H9c2 cells?
Does visfatin induce cardiomyocyte hypertrophy via the ERK1/2 signaling pathway in H9c2 cells?
Visfatin induces cardiomyocyte hypertrophy through the activation of the ERK1/2 signaling pathway in H9c2 embryonic rat cardiac cells.
May promote hypertrophy via ERK1/2 in rat cardiomyocytes; leaves open relevance to human cardiac remodeling and requires in vivo validation.
Background and Objective: Visfatin is an adipokine which is abundantly expression in visceral adipose tissue. It has insulin-like effect and hypoglycemic effect. Visfatin can induce the production of inflammatory factors and myocardial hypertrophy but the exact molecular mechanisms remain unclear. The purpose of this study was to investigate the underlying molecular mechanism that visfatin induces cardiomyocyte hypertrophy. Materials and Methods: H9c2 cells were cultured and treated with visfatin. Cell surface area was measured with ImageJ software. Protein synthesis was calculated by dividing the protein content by the cell number. BNP, "-SMA, p-ERK1/2 and ERK1/2 protein expression were detected by Western blotting. Results: The results showed that visfatin induced cell surface area, protein synthesis, BNP, "-SMA and p-ERK1/2 protein expression increase significantly. Pre-treatment with MAPK Kinase Inhibitor PD98059 of ERK1/2 signaling pathway significantly attenuated these effects of visfatin. Conclusion: The results suggested that visfatin induces cardiomyocyte hypertrophy through the activation of ERK1/2 signaling pathway.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2019) studied Cardiomyocyte hypertrophy. Visfatin vs. MAPK Kinase Inhibitor PD98059 pre-treatment / Control was evaluated on Cell surface area, protein synthesis, BNP, α-SMA and p-ERK1/2 protein expression. Visfatin induced cardiomyocyte hypertrophy through the activation of the ERK1/2 signaling pathway, an effect significantly attenuated by pre-treatment with MAPK Kinase Inhibitor PD98059.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: